However, comparative clinical outcomes of third-generation versus second-generation CD19 CAR-T cells in targeting B cell non-Hodgkin lymphoma indicate superior persistence and up to 40-fold greater expansion for the third-generation CD19 CAR-T cells.33 This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.